[1] |
Guanen Q,Junjie S,Baolin W,et al.MiR-214 promotes cell meastasis and inhibites apoptosis of esophageal squamous cell carcinoma via PI3K/AKT/mTOR signaling pathway[J].Biomed Pharmacother,2018,105:350-361.
|
[2] |
Manning BD,Toker A.AKT/PKB Signaling:Navigating the Network[J].Cell,2017,169(3):381-405.
|
[3] |
Fruman DA,Chiu H,Hopkins BD,et al.The PI3K Pathway in Human Disease[J].Cell,2017,170(4):605-635.
|
[4] |
Manning BD,Cantley LC.AKT/PKB signaling:navigating downstreamk[J].Cell,2007,129(7):1261-1274.
|
[30] |
Weichhart T.mTOR as Regulator of Lifespan,Aging,and Cellular Senescence:A Mini-Review[J].Gerontology,2018,64(2):127-134.
|
[31] |
Yang H,Rudge DG,Koos JD,et al.mTOR kinase structure,mechanism and regulation[J].Nature,2013,497(7448):217-223.
|
[5] |
JavadiniaSA,ShahidsalesS,Fanipakdel A,et al.The Esophageal Cancer and the PI3K/AKT/mTOR Signaling Regulatory microRNAs:a Novel Marker for Prognosis,and a Possible Target for Immunotherapy[J].Curr Pharm Des,2018,24(39):4646-4651.
|
[6] |
Tasioudi KE,Sakellariou S,Levidou G,et al.Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma[J].APMIS,2015,123(8):639-647.
|
[7] |
Li B,Xu WW,Lam AKY,et al.Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy[J].Oncotarget,2017,8(24):38 755-38 766.
|
[8] |
Zhang LN,Zhao L,Yan XL,et al.Loss of G3BP1 suppresses proliferation,migration,and invasion of esophageal cancer cells via Wnt/β-catenin and PI3K/AKT signaling pathways[J].J Cell Physiol,2019,234(11):20 469-20 484.
|
[9] |
Sheng J,Deng X,Zhang Q,et al.PAR-2 promotes invasion and migration of esophageal cancer cells by activating MEK/ERK and PI3K/Akt signaling pathway[J].Int J Clin Exp Pathol,2019,12(3):787-797.
|
[10] |
Wang G,Sun J,Zhao H,et al.Long Non-Coding RNA (lncRNA)Growth Arrest Specific 5(GAS5)Suppresses Esophageal Squamous Cell Carcinoma Cell Proliferation and Migration by Inactivating Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway[J].Med Sci Monit,2018,24:7689-7696.
|
[11] |
Xia D,Tian S,Chen Z,et al.miR302a inhibits the proliferation of esophageal cancer cells through the MAPK and PI3K/Akt signaling pathways[J].Oncol Lett,2018,15(3):3937-3943.
|
[12] |
Chen HX,Liu YS,Zhang XJ.TargetScore used to reveal potential targets of miRNA203 and miRNA-146a in psoriasis by integrating microRNA overexpression and microarray data[J].Medicine (Baltimore),2018,97(41):e12671.
|
[13] |
Xia Y,Wang Y,Wang Q,et al.Increased miR-203-3p and reduced miR-21-5p synergistically inhibit proliferation,migration,and invasion in esophageal cancer cells[J].Anticancer Drugs,2019,30(1):38-45.
|
[14] |
Yuan Y,Zeng ZY,Liu XH,et al.MicroRNA-203 inhibits cell proliferation by repressing ΔNp63 expression in human esophageal squamous cell carcinoma[J].BMC Cancer,2011,11:57.
|
[15] |
Takeshita N,Mori M,Kano M,et al.miR-203 inhibits the migration and invasion of esophageal squamous cell carcinoma by regulating LASP1[J].Int J Oncol,2012,41(5):1653-1661.
|
[18] |
殷彩桥,方呈祥,陈婷,等.miR-203a-3p 通过靶向调控GATA6 抑制食管鳞癌细胞的增殖和侵袭[J].中国癌症杂志,2020,30(6):441-448.
|
[19] |
Wang L,Zhang Z,Yu X,et al.SOX9/miR-203a axis drives PI3K/AKT signaling to promote esophageal cancer progression[J].Cancer Lett,2020,468:14-26.
|
[29] |
Shi N,Yu H,Chen T.Inhibition of esophageal cancer growth through the suppression of PI3K/AKT/mTOR signaling pathway[J].Onco Targets Ther,2019,12:7637-7647.
|
[16] |
Zhang F,Yang Z,Cao M,et al.MiR-203 suppresses tumor growth and invasion and down-regulates MiR-21 expression through repressing Ran in esophageal cancer[J].Cancer Lett,2014,342(1):121-129.
|
[17] |
Zong M,Feng W,Wan L,et al.miR-203 affects esophageal cancer cell proliferation,apoptosis and invasion by targeting MAP3K1[J].Oncol Lett,2020,20(1):751-757.
|
[20] |
Alqahtani A,Ayesh HSK,Halawani H.PIK3CA Gene Mutations in Solid Malignancies:Association with Clinicopathological Parameters and Prognosis[J].Cancers(Basel),2019,12(1):93.
|
[21] |
Zhang A,Lakshmanan J,Motameni A,et al.MicroRNA-203 suppresses proliferation in liver cancer associated with PIK3CA,p38 MAPK,c-Jun,and GSK3 signaling[J].Mol Cell Biochem,2018,441(1-2):89-98.
|
[22] |
Pereira L,Horta S,Mateus R,et al.Implications of Akt2/Twist crosstalk on breast cancer metastatic outcome[J].Drug Discov Today,2015,20(9):1152-1158.
|
[23] |
Li J,Chen Y,Zhao J,et al.miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression[J].Cancer Lett,2011,304(1):52-59.
|
[24] |
Wang-Bishop L,Chen Z,Gomaa A,et al.Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1[J].Gastroenterology,2019,156(3):662-675.e7.
|
[25] |
Hancox U,Cosulich S,Hanson L,et al.Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel[J].Mol Cancer Ther,2015,14(1):48-58.
|
[26] |
Caino MC,Ghosh JC,Chae YC,et al.PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion[J].Proc Natl Acad Sci U S A,2015,112(28):8638-8643.
|
[27] |
Molife LR,Yan L,Vitfell-Rasmussen J,et al.Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel,docetaxel,or erlotinib in patients with advanced solid tumors[J].J Hematol Oncol,2014,7:1.
|
[28] |
Ou DL,Lee BS,Lin LI,et al.Vertical blockade of the IGFRPI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma:the role of survivin[J].Mol Cancer,2014,13:2.
|
[32] |
Conciatori F,Ciuffreda L,Bazzichetto C,et al.mTOR Cross-Talk in Cancer and Potential for Combination Therapy[J].Cancers(Basel),2018,10(1):23.
|
[33] |
Zhang CΗ,Awasthi N,Schwarz MA,et al.The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer[J].Int J Oncol,2013,43(5):1627-1635.
|
[34] |
Manara MC,Nicoletti G,Zambelli D,et al.NVP-BEZ235 as a new therapeutic option for sarcomas[J].Clin Cancer Res,2010,16(2):530-540.
|
[35] |
Liu H,Zhao J,Fu R,et al.The ginsenoside Rk3 exerts anti-esophageal cancer activity in vitro and in vivo by mediating apoptosis and autophagy through regulation of the PI3K/Akt/mTOR pathway[J].PLoS One,2019,14(5):e0216 759.
|
[36] |
Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
|
[37] |
Tang JC,An R,Jiang YQ,et al.Effects and Mechanisms of Metformin on the Proliferation of Esophageal Cancer Cells In Vitro and In Vivo[J].Cancer Res Treat,2017,49(3):778-789.
|
[38] |
Jin Y,Xu K,Chen Q,et al.Simvastatin inhibits the development of radioresistant esophageal cancer cells by increasing the radiosensitivity and reversing EMT process via the PTEN-PI3K/AKT pathway[J].Exp Cell Res,2018,362(2):362-369.
|